Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Macrogenics (NASDAQ:MGNX), Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Atossa Therapeutics (NASDAQ:ATOS) and Adaptimmune Therapeutics (NASDAQ:ADAP).
Cellectis has a consensus price target of $9.50.
The stock price for Cellectis (NASDAQ: CLLS) is $2.135 last updated September 18, 2024 at 7:23 PM EDT.
There are no upcoming dividends for Cellectis.
Cellectis’s Q3 earnings are confirmed for Monday, November 4, 2024.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.